Mural Oncology plc financial data

Symbol
MURA on Nasdaq
Location
10 Earlsfort Terrace, Dublin 2, Ireland
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 469 % -48.7%
Debt-to-equity 25.5 % +77.7%
Return On Equity -131 % -87.5%
Return On Assets -105 % -70.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 17.3M shares +1.67%
Common Stock, Shares, Outstanding 17.3M shares +1.68%
Entity Public Float 32.2M USD
Common Stock, Value, Issued 174K USD +2.35%
Weighted Average Number of Shares Outstanding, Basic 17.3M shares +1.72%
Weighted Average Number of Shares Outstanding, Diluted 17.3M shares +1.72%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 107M USD -21.9%
General and Administrative Expense 30.5M USD -16.9%
Operating Income (Loss) -123M USD +23.5%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -119M USD +22.6%
Earnings Per Share, Basic -6 USD/shares +24.2%
Earnings Per Share, Diluted -6 USD/shares +24.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 58.9M USD -47%
Other Assets, Current 364K USD -51.5%
Assets, Current 62.2M USD -66.2%
Property, Plant and Equipment, Net 466K USD -94.7%
Operating Lease, Right-of-Use Asset 3.13M USD -63.7%
Other Assets, Noncurrent 3K USD -96.1%
Assets 65.8M USD -67.7%
Accounts Payable, Current 3.14M USD +1.09%
Employee-related Liabilities, Current 4.29M USD -21%
Accrued Liabilities, Current 6.79M USD -60.5%
Liabilities, Current 10.5M USD -57.7%
Operating Lease, Liability, Noncurrent 42K USD -99%
Other Liabilities, Noncurrent 0 USD -100%
Liabilities 10.6M USD -63.7%
Retained Earnings (Accumulated Deficit) -244M USD -95.2%
Stockholders' Equity Attributable to Parent 55.2M USD -68.3%
Liabilities and Equity 65.8M USD -67.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -36.8M USD +1.45%
Net Cash Provided by (Used in) Financing Activities 28M USD
Net Cash Provided by (Used in) Investing Activities 28M USD
Common Stock, Shares Authorized 450M shares 0%
Common Stock, Shares, Issued 17.3M shares +1.68%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.78M USD +94.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 60.6M USD -46.4%
Deferred Tax Assets, Valuation Allowance 50.7M USD +755%
Operating Lease, Liability 3.55M USD -62.8%
Depreciation 3.62M USD +13.6%
Payments to Acquire Property, Plant, and Equipment 10K USD -81.8%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -119M USD +22.5%
Lessee, Operating Lease, Liability, to be Paid 3.6M USD -63.5%
Property, Plant and Equipment, Gross 32.8M USD -27.4%
Operating Lease, Liability, Current 3.51M USD -35.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.48M USD -62.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.48M USD -62.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.04 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 53K USD -83.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.48M USD
Deferred Tax Assets, Operating Loss Carryforwards 8.21M USD +1049%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 299M USD +0.06%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 2.17M USD -34.8%
Share-based Payment Arrangement, Expense 163K USD -99.2%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%